Start-up investment achieves receives FDA Breakthrough Device Designation
Renovos was ORUK’s first investment in an MSK start-up. We are therefore delighted that the company has received FDA Breakthrough Device Designation for its proprietary, synthetic nano clay bone fusion gel, RENOVITE. This is an important milestone for the company.
According to Dr Agnieszka Janeczek, Chief Executive Officer of Renovos Biologics, ‘The accelerated regulatory feedback and prioritised review will shorten the time to market and allow faster access to expanded treatment options for patients suffering from degenerative disc disease.’
For further information, follow this link.
In the spirit of our founder Ronald Furlong, who combined a highly successful career as an orthopaedic surgeon with an equally successful career as an entrepreneur, we are the first MSK charity to actively support start-ups and entrepreneurs. With the Ronald Furlong Fund for Start-ups and the Grand Challenge Award, co-funded by the British Hip Society, our aim is to accelerate the roll-out of innovative ideas such as RENOVITE.